Founding Intercept CEO Pruzanski prepares to hand over the reins 

For the first time in its nearly 20-year history, Intercept will ring in the New Year with a new face in the corner office.

After guiding Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) through its launch in the years immediately after the bursting of the genomics bubble to an $86 million IPO in 2012 and the approval of its first marketed product in Ocaliva obeticholic acid, President and CEO Mark Pruzanski is handing over the reins to his COO, Jerry Durso. Pruzanski will become an adviser to the company and remain on its board...